Study on risk reducing salpingo-oophorectomy(RRSO) for BRCA1/2 mutation carriers
Not Applicable
Recruiting
- Conditions
- hereditary breast and ovarian cancer
- Registration Number
- JPRN-UMIN000005292
- Lead Sponsor
- Cancer Institute Hospital Department of Gynecology, Breast center, Clinical Genetic Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1.She desires having babies. 2.The case in which IRB doesn't approve to perform PBSO.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety and outcome of risk reducing bilateral salpingo-oophorectomy
- Secondary Outcome Measures
Name Time Method actual medical fee for RRSO pathological findings of resested specimen for PBSO satisfaction with PBSO
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are affected by RRSO in BRCA1/2 mutation carriers to reduce ovarian cancer risk?
How does RRSO compare to ovarian surveillance in preventing cancer in BRCA1/2 carriers?
Which biomarkers beyond BRCA1/2 status predict response to RRSO in hereditary breast and ovarian cancer?
What are the long-term adverse effects of RRSO in BRCA1/2 mutation carriers and their management?
Are PARP inhibitors or hormonal therapies used alongside RRSO for BRCA1/2 carriers in clinical practice?